1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO

IPO Priced At Top Of Stock Price Band

 
• By Jung Won Shin

Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.

human cells and veins
ViGenCell Developing Both Autologous And Universal Cell Therapies • Source: Alamy

Immune cell therapy company ViGenCell Inc. has kept the biopharma investment fervor going in South Korea, raising KRW99.4bn ($85m) from an initial public offering on the Kosdaq market.

The stock was priced at the top end of the KRW42,800-52,700 band and the offering was oversubscribed 886.2 times by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.